Safety pharmacology
Reading File
Finding Sources
Searching the Web
safety pharmacology ICH S7A S7B guidelines overview
Finding Sources
Finding Sources
Finding Sources
Reading Web Page
safety pharmacology definition objectives core battery studies
Finding Sources
Finding Sources
Reading File
Finding Sources
Now I have enough material for a thorough response. Let me compile the full answer.
Safety Pharmacology
Definition
Safety pharmacology is defined (per ICH S7A) as the discipline that investigates "potential undesirable pharmacodynamic effects of a substance on physiological functions in relation to exposure in the therapeutic range and above." It is a mandatory component of preclinical drug development, distinct from traditional toxicology because it focuses on functional organ-system effects rather than structural/histological damage.
Purpose and Objectives
- Identify pharmacodynamic properties of a new drug that could be hazardous to patients.
- Evaluate dose-response relationships for observed adverse effects.
- Determine the onset, duration, and reversibility of those effects.
- Assess mechanisms when adverse effects are found.
- Inform design of clinical studies and post-marketing surveillance.
Regulatory Framework - ICH Guidelines
Safety pharmacology is governed by two core ICH guidelines:
| Guideline | Scope |
|---|---|
| ICH S7A | Core battery and supplemental studies for all new chemical/biological entities |
| ICH S7B | Specific guidance on evaluating cardiac repolarization (QT/QTc prolongation risk) |
Studies must generally be conducted under Good Laboratory Practice (GLP). The core battery must be completed before first administration in humans.
The Core Battery (ICH S7A - Three Vital Systems)
1. Central Nervous System (CNS)
- Parameters assessed: motor activity, behavioral changes, coordination, sensory/motor reflex responses, body temperature
- Methods: Functional Observation Battery (FOB), modified Irwin screen in rodents; large-animal neurological evaluations
- Purpose: Detect sedation, stimulation, seizure liability, neurotoxicity
2. Cardiovascular System
- Parameters assessed: blood pressure, heart rate, ECG (QRS morphology, PR interval, QT interval), ventricular/pulmonary pressure
- Methods: Jacketed external telemetry (JET) or implanted telemetry in conscious unrestrained animals (dogs, minipigs, primates)
- In vitro: hERG (Kv11.1) channel assay (action potential prolongation)
- Purpose: Detect arrhythmia risk, hemodynamic changes, cardiac repolarization abnormalities
3. Respiratory System
- Parameters assessed: respiratory rate, tidal volume, minute volume, hemoglobin oxygen saturation (SpO2)
- Methods: Whole-body or head-out plethysmography
- Purpose: Detect respiratory depression, bronchoconstriction, changes in pattern of breathing
Follow-Up and Supplemental Studies (ICH S7A Section 2.8)
When the core battery raises a concern, or based on scientific rationale, additional studies are required:
| System | Examples |
|---|---|
| CNS | Behavioral pharmacology, learning and memory, specific receptor binding studies, addiction/dependence liability |
| Cardiovascular | Cardiac action potential in isolated tissue, vascular tone studies |
| Respiratory | Airway resistance, blood gas analysis |
| Renal/Urinary | Urine volume, osmolarity, electrolyte excretion |
| Autonomic NS | Baroreflex sensitivity, heart rate variability |
| Gastrointestinal | Gastric secretion, GI motility/transit |
The hERG Channel and Cardiac Repolarization
This is one of the most clinically important areas of safety pharmacology. The hERG (Kv11.1, KCNH2) channel carries the rapid delayed rectifier potassium current (IKr), which is critical for cardiac repolarization.
- The problem: The hERG channel has an unusually large inner cavity that can bind a wide variety of structurally dissimilar drug molecules - an example of "promiscuity of the target" rather than the drug.
- Consequence: Block of hERG prolongs the cardiac action potential → prolonged QT interval on ECG → risk of Torsades de Pointes (TdP), a potentially fatal polymorphic ventricular arrhythmia.
- Examples: Terfenadine (antihistamine), cisapride (prokinetic), and thioridazine were withdrawn or restricted because of hERG-mediated TdP.
- ICH S7B specifically addresses how to test for this liability using in vitro hERG assays, in vivo QT measurement, and eventually a thorough QT (TQT) study in humans under ICH E14.
As stated in Goodman & Gilman: "A common mechanism by which drugs prolong action potentials in the heart and provoke arrhythmias is inhibition of a specific delayed rectifier current generated by hERG (Kv11.1)." - Goodman & Gilman's Pharmacological Basis of Therapeutics
Timing in Drug Development
| Stage | Safety Pharmacology Requirement |
|---|---|
| Before first-in-human (FIH) | Full core battery (CNS, CV, Respiratory) |
| During clinical development | Follow-up studies if new signals emerge |
| Before approval | All supplemental system studies (renal, ANS, GI) if relevant |
Special Considerations
- Metabolites: Major human metabolites not covered by parent drug testing require their own studies. In vitro systems are acceptable.
- Isomers: When a product contains an isomeric mixture, testing of individual isomers should be considered.
- Formulations: New formulations that substantially alter PK/PD (e.g., liposomes, penetration enhancers) require repeat studies.
- Biopharmaceuticals: Peptides, proteins, and antibodies may not require the full core battery if species-specific issues (e.g., no receptor cross-reactivity in standard models) preclude meaningful testing.
Safety Pharmacology vs. Toxicology - Key Differences
| Feature | Safety Pharmacology | Toxicology |
|---|---|---|
| Focus | Functional organ effects | Structural/histological damage |
| Endpoints | Physiological (BP, HR, EEG) | Cell death, organ damage biomarkers |
| Timing | Acute/subacute | Acute to chronic |
| Design | Single organ/system studies | Multi-organ, repeat-dose |
| Models | Conscious, unrestrained animals preferred | Can use anesthetized or histological |
Summary
Safety pharmacology is the gateway between drug discovery and human trials. Its primary goal is to characterize adverse effects on the CNS, cardiovascular, and respiratory systems before a drug enters humans. The cardiovascular system - particularly hERG-mediated QT prolongation - receives the most regulatory scrutiny because of its direct link to life-threatening arrhythmias. The ICH S7A guideline remains the definitive regulatory document governing these studies.
This is a shared conversation. Sign in to Orris to start your own chat.